voretigene neparvovec

AXP000249.1 · Viral vector gene therapy

Platform
AAV2 vector
Targets
RPE65
Originator
Spark Therapeutics
Sponsor
Spark Therapeutics (Roche)

Names

NameTypeSource
voretigene neparvovecpreferred namecurator
Luxturnabrandfda
AAV2-hRPE65v2former codecurator

Virus

Role
In vivo gene transfer
Family
Parvoviridae
Virus
adeno-associated virus 2
Strain
AAV2
Replication
non replicating
Transgenes
RPE65
Route
subretinal
Source
evidence

Approvals

AgencyRegionDateStatusBrandIndicationSource
FDAUS2017-12-19approvedLuxturnaBiallelic RPE65 mutation-associated retinal dystrophysource
EMAEU2018-11-22approvedLuxturnaVision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations, with sufficient viable retinal cellssource
PMDAJP2023-06-26approvedLuxturnaBiallelic RPE65 mutation-associated inherited retinal dystrophysource

Clinical trials (6)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04516369Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal DystrophyCompletedPhase 32020-11-242022-04-054Biallelic RPE65 Mutation-associated Retinal Dystrophy
NCT03597399A Patient Registry Study for Patients Treated With Voretigene Neparvovec in USCompleted2019-01-102025-06-3087Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy
NCT03602820Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)Active not recruiting2015-062030-0141Inherited Retinal Dystrophy Due to RPE65 Mutations
NCT00999609Safety and Efficacy Study in Subjects With Leber Congenital AmaurosisActive not recruitingPhase 32012-102015-0731Inherited Retinal Dystrophy Due to RPE65 Mutations; Leber Congenital Amaurosis
NCT01208389Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2Active not recruitingPhase 1/22010-112027-1012Leber Congenital Amaurosis
NCT00516477Safety Study in Subjects With Leber Congenital AmaurosisCompletedPhase 12007-092018-03-2012Leber Congenital Amaurosis

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41845931A heterozygous pathogenic RPE65 variant phenocopies a mitochondrial retinopathy.Ophthalmic genetics2026name in abstract: voretigene neparvovec
PMID 42192584Four-Year Structural and Functional Outcomes of the First Subretinal Voretigene Neparvovec-rzyl Treatment for RPE65-Associated Inherited Retinal Dystrophy in South Korea.Korean journal of ophthalmology : KJO2026name in title: voretigene neparvovec
PMID 42624634Reverse amblyopia following gene therapy-induced visual improvement in a child with retinal pigment epithelium-65 inherited retinal dystrophy.BMJ case reports2026name in abstract: voretigene neparvovec
PMID 42693233Delayed foveal atrophy following early visual improvement after voretigene neparvovec gene therapy in a child.Eye (London, England)2026name in title: voretigene neparvovec
PMID 42755963Sustained improvement in dark-adapted sensitivity but not BCVA after voretigene neparvovec treatment in a mainland Chinese child with biallelic RPE65-associated LCA2: a case report.Frontiers in pharmacology2026name in title: voretigene neparvovec
PMID 39788486"Blindness" is not a contraindication for voretigene neparvovec-rzyl treatment: a review of 9 cases.Canadian journal of ophthalmology. Journal canadien d'ophtalmologie2025name in title: voretigene neparvovec
PMID 39835736A Korean Patient With Leber Congenital Amaurosis and a Homozygous RPE65 Variant Originating From a Paternal Uniparental Isodisomy.Molecular genetics & genomic medicine2025name in abstract: voretigene neparvovec
PMID 40757766Short-Term Outcomes of Pediatric Patients With Mild Autosomal Recessive RPE65-Associated Retinal Dystrophy Treated With Voretigene Neparvovec.Translational vision science & technology2025name in title: voretigene neparvovec
PMID 37660736Classification and Growth Rate of Chorioretinal Atrophy after Voretigene Neparvovec-Rzyl for RPE65-Mediated Retinal Degeneration.Ophthalmology. Retina2024name in title: voretigene neparvovec
PMID 38254722Real-World Safety and Effectiveness of Voretigene Neparvovec: Results up to 2 Years from the Prospective, Registry-Based PERCEIVE Study.Biomolecules2024cited by trial NCT00516477
PMID 38888288Perimacular Atrophy Following Voretigene Neparvovec-Rzyl Treatment in the Setting of Previous Contralateral Eye Treatment With a Different Viral Vector.Translational vision science & technology2024name in title: voretigene neparvovec
PMID 39062658Myopic Macular Hole and Detachment after Gene Therapy in Atypical RPE65 Retinal Dystrophy: A Case Report.Genes2024name in abstract: voretigene neparvovec
PMID 35904185Pathogenicity reclassification of the RPE65 c.1580A>G (p.His527Arg) - a case report.Ophthalmic genetics2023name in abstract: voretigene neparvovec
PMID 37521805Bilateral exudative retinal detachments after subretinal gene therapy with voretigene neparvovec-rzyl for RPE65 Leber Congenital Amaurosis.American journal of ophthalmology case reports2023name in title: voretigene neparvovec
PMID 33838313Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis.Ophthalmology. Retina2022name in title: voretigene neparvovec
PMID 34289237Short term morphological rescue of the fovea after gene therapy with voretigene neparvovec.Acta ophthalmologica2022name in title: voretigene neparvovec
PMID 34896323Visual Acuity, Retinal Morphology, and Patients' Perceptions after Voretigene Neparovec-rzyl Therapy for RPE65-Associated Retinal Disease.Ophthalmology. Retina2022name in abstract: voretigene neparvovec
PMID 35748082Short-Term Outcomes of the First in Vivo Gene Therapy for RPE65-Mediated Retinitis Pigmentosa.Yonsei medical journal2022name in abstract: voretigene neparvovec
PMID 35765055Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.BMC health services research2022cited by trial NCT00999609
PMID 36034763Iatrogenic choroidal neovascularization associated with subretinal gene therapy surgery.American journal of ophthalmology case reports2022name in abstract: voretigene neparvovec
PMID 36142423RPE65 c.353G>A, p.(Arg118Lys): A Novel Point Mutation Associated with Retinitis Pigmentosa and Macular Atrophy.International journal of molecular sciences2022name in abstract: voretigene neparvovec
PMID 36225124Chorioretinal atrophy following voretigene neparvovec despite the presence of fundus autofluorescence.Molecular genetics & genomic medicine2022name in title: voretigene neparvovec
PMID 33798654Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years.Ophthalmology2021name in title: voretigene neparvovec
PMID 34158306Perspectives of people with inherited retinal diseases on ocular gene therapy in Australia: protocol for a national survey.BMJ open2021name in abstract: voretigene neparvovec
PMID 32081601Macular Fold Complicating a Subretinal Injection of Voretigene Neparvovec.Ophthalmology. Retina2020name in title: voretigene neparvovec
PMID 32556084Quantitative Autofluorescence Following Gene Therapy With Voretigene Neparvovec.JAMA ophthalmology2020name in title: voretigene neparvovec
PMID 31044739Bilateral Subretinal Voretigene Neparvovec-rzyl (Luxturna) Gene Therapy.Ophthalmology. Retina2019name in title: voretigene neparvovec
PMID 31443789Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.Ophthalmology2019name in title: voretigene neparvovec
PMID 31580392Utility of In Vitro Mutagenesis of RPE65 Protein for Verification of Mutational Pathogenicity Before Gene Therapy.JAMA ophthalmology2019name in abstract: voretigene neparvovec
PMID 31671202Subretinal Injection of Voretigene Neparvovec-rzyl in a Patient With RPE65-Associated Leber's Congenital Amaurosis.Ophthalmic surgery, lasers & imaging retina2019name in title: voretigene neparvovec
PMID 28712537Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.Lancet (London, England)2017cited by trial NCT00999609
PMID 27375040Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.Lancet (London, England)2016cited by trial NCT01208389
PMID 22323828AAV2 gene therapy readministration in three adults with congenital blindness.Science translational medicine2012cited by trial NCT00999609
PMID 22812667Pupillometric analysis for assessment of gene therapy in Leber Congenital Amaurosis patients.Biomedical engineering online2012cited by trial NCT00516477
PMID 21606598The human visual cortex responds to gene therapy-mediated recovery of retinal function.The Journal of clinical investigation2011cited by trial NCT00516477
PMID 19953081Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration.Molecular therapy : the journal of the American Society of Gene Therapy2010cited by trial NCT00516477
PMID 19854499Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.Lancet (London, England)2009cited by trial NCT00516477
PMID 18441370Safety and efficacy of gene transfer for Leber's congenital amaurosis.The New England journal of medicine2008cited by trial NCT00516477

Other papers

Preclinical studies, reviews and other papers that name it, newest 100 shown.

PubMedTitleJournalYearLinked by
PMID 40148593Organoids - the future of pre-clinical development of AAV gene therapy for CNS disorders.Gene therapy2026name in abstract: Luxturna
PMID 41343897Promises past and future - Gene therapy and the actualisation of future expectations.Social science & medicine (1982)2026name in abstract: Luxturna
PMID 41379738Chorioretinal Atrophy after Voretigene Neparvovec Therapy in RPE65 Mutation-Associated Inherited Retinal Disease: Longitudinal Characterization in Multimodal Imaging.Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde2026name in title: voretigene neparvovec
PMID 41481309Vision Outcomes in Children Treated With Voretigene Neparvovec for RPE65-Associated Retinopathy.JAMA ophthalmology2026name in title: voretigene neparvovec
PMID 41520727Biologics-device combinations: Enabling prolonged therapies in the posterior segment ocular disease.Advanced drug delivery reviews2026name in abstract: Luxturna
PMID 41679721Gene therapy outcomes in young patients with RPE65-retinal degeneration.Canadian journal of ophthalmology. Journal canadien d'ophtalmologie2026name in abstract: voretigene neparvovec
PMID 41758347Real-world safety of voretigene neparvovec: a disproportionality analysis for signal detection using the FAERS database.Naunyn-Schmiedeberg's archives of pharmacology2026name in title: voretigene neparvovec
PMID 41853567Expert Consensus on Characteristics, Etiology, and Management of Chorioretinal Atrophy in Patients Treated with Voretigene Neparvovec.Ophthalmology science2026name in title: voretigene neparvovec
PMID 41933930Adeno-Associated Virus Gene Delivery to Hard-to-Transduce Tissues: Biological Barriers, Engineering Strategies, and Clinical Challenges.Human gene therapy2026name in abstract: Luxturna
PMID 41998128Structural, functional and patient-reported 24-month outcomes of voretigene neparvovec in Portuguese patients with RPE65-associated disease.Eye (London, England)2026name in title: voretigene neparvovec
PMID 42074510Gene-Agnostic Therapeutic Strategies for Inherited Retinal Diseases: Neuroprotection and Immunomodulation.Genes2026name in abstract: voretigene neparvovec
PMID 42117798Voretigene Neparvovec Gene Therapy in Clinical Practice: A 12-Month, Single-Center, In-Depth Analysis of Beneficial and Adverse Drug Effects.Translational vision science & technology2026name in title: voretigene neparvovec
PMID 42137601Single-cell and spatial transcriptomic analyses of gene therapy-associated retinal inflammation in non-human primates.Molecular therapy. Advances2026name in abstract: voretigene neparvovec
PMID 42299455Microperimetry is a valuable tool for assessing changes in visual function following voretigene neparvovec-rzyl gene therapy.Ophthalmic genetics2026name in title: voretigene neparvovec
PMID 42331100Clinical Experience with Gene Therapy for Autosomal Recessive RPE65-Related Retinal Dystrophy in the United Arab Emirates.Ophthalmology. Retina2026name in abstract: voretigene neparvovec
PMID 42346599Genetic Testing in Inherited Retinal Disease: Current Strategies and Future Directions.Journal of personalized medicine2026name in abstract: voretigene neparvovec
PMID 42346603Precision Medicine in Inherited Retinal Disease: Advances, Challenges, and Future Directions.Journal of personalized medicine2026name in abstract: Luxturna
PMID 42365082Clinical and genetic characteristics of RPE65-associated inherited retinal degeneration in Koreans.Scientific reports2026name in abstract: voretigene neparvovec
PMID 42425207Post-approval outcomes of voretigene neparvovec (Luxturna®) retinal gene therapy: A systematic review and meta-analysis.Survey of ophthalmology2026name in title: voretigene neparvovec
PMID 42449943Trends in the Engineering of Adeno-Associated Virus (AAV) for Precision Gene Delivery to the Central Nervous System (CNS).International journal of molecular sciences2026name in abstract: Luxturna
PMID 42486371Interim Results from a Multicenter Observational Safety Study of Patients Treated with Voretigene Neparvovec-Rzyl in the United States.Ophthalmology2026name in title: voretigene neparvovec
PMID 42674265Voretigene Neparvovec (Luxturna) for Biallelic RPE65-Associated Retinal Dystrophy: Systematic Review.American journal of ophthalmology2026name in title: voretigene neparvovec
PMID 42839681The Price of a Cure: Luxturna and the Economic Dilemmas of Precision Medicine.The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics2026name in title: Luxturna
PMID 42848340Durable Safety and Efficacy of Voretigene Neparvovec-Rzyl in Postapproval Studies in the USA: CRAning for Perfection.Ophthalmology2026name in title: voretigene neparvovec
PMID 42901316Mastering the eye: Clinical paradigm shifts from optical restoration to genomic correction.Progress in retinal and eye research2026name in abstract: voretigene neparvovec
PMID 42927978Does Route of Administration Affect the Outcome of Retinal Gene Therapy Clinical Trials?Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics2026name in abstract: voretigene neparvovec
PMID 39039945Genetic counselors' awareness and attitudes regarding gene therapies.Journal of genetic counseling2025name in abstract: voretigene neparvovec
PMID 39418576THE FIGHT INHERITED RETINAL BLINDNESS! PROJECT: A New Treatment Outcome and Natural History Registry for Inherited Retinal Disease.Retina (Philadelphia, Pa.)2025name in abstract: voretigene neparvovec
PMID 3957801912-month outcomes after voretigene neparvovec gene therapy in paediatric patients with RPE65-mediated inherited retinal dystrophy.The British journal of ophthalmology2025name in title: voretigene neparvovec
PMID 39739008Canine models of inherited retinal diseases: from neglect to well-recognized translational value.Mammalian genome : official journal of the International Mammalian Genome Society2025name in abstract: voretigene neparvovec
PMID 39745677Deep Learning-Based SD-OCT Layer Segmentation Quantifies Outer Retina Changes in Patients With Biallelic RPE65 Mutations Undergoing Gene Therapy.Investigative ophthalmology & visual science2025name in abstract: voretigene neparvovec
PMID 39828244Insights into the effects of subretinal voretigene neparvovec-rzyl in RPE65-associated Leber congenital amaurosis.Canadian journal of ophthalmology. Journal canadien d'ophtalmologie2025name in title: voretigene neparvovec
PMID 39900645Real-world outcomes of Voretigene Neparvovec: a single-centre consecutive case series.Eye (London, England)2025name in title: voretigene neparvovec
PMID 39920348Foveal detachment in voretigene neparvovec administration: essential step or avoidable risk?Eye (London, England)2025name in title: voretigene neparvovec
PMID 39941570Pre-Clinical and Clinical Advances in Gene Therapy of X-Linked Retinitis Pigmentosa: Hope on the Horizon.Journal of clinical medicine2025name in abstract: Luxturna
PMID 39943983Long-term experience with gene augmentation therapy in patients with inherited retinal disease associated with biallelic mutations in RPE65.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V2025name in abstract: voretigene neparvovec
PMID 39956654Evaluating ocular health in retinal gene therapies.Clinical & experimental optometry2025name in abstract: voretigene neparvovec
PMID 39989340A Comprehensive Review of Clinically Applied Adeno-Associated Virus-Based Gene Therapies for Ocular Disease.Human gene therapy2025name in abstract: Luxturna
PMID 40027263Cell-penetrating peptide-grafted AAV2 capsids for improved retinal delivery via intravitreal injection.Molecular therapy. Methods & clinical development2025name in abstract: Luxturna
PMID 40087508Voretigene neparvovec in RPE65-related inherited retinal dystrophy: the 1-year real-world study LIGHT.Eye (London, England)2025name in title: voretigene neparvovec
PMID 40104153Validation of a quantitative cell-based relative potency assay for LUXTURNA.Molecular therapy. Methods & clinical development2025name in title: Luxturna
PMID 40204976Improvements induced by retinal gene therapy with voretigene neparvovec depend on visual cortical hemispheric dominance mechanisms.Communications medicine2025name in title: voretigene neparvovec
PMID 40268248Retina-directed gene therapy: Achievements and remaining challenges.Pharmacology & therapeutics2025name in abstract: voretigene neparvovec
PMID 40334704Correction: Letter to the editor relating to Stingl K, Priglinger C, Herrmann P. "RPE65-Associated Retinal Dystrophies: Phenotypes and Treatment Effects with Voretigene Neparvovec" Klin Monbl Augenheilkd 2024; 241(03): 259-265. DOI: 10.1055/a-2227-3671.Klinische Monatsblatter fur Augenheilkunde2025name in title: voretigene neparvovec
PMID 40602323Viral and non-viral vectors in gene therapy: current state and clinical perspectives.EBioMedicine2025name in abstract: Luxturna
PMID 40689376Assessment of the official national insurance coverage of regenerative medical products for ophthalmic diseases in Japan following regulatory approval.Regenerative therapy2025name in abstract: Luxturna
PMID 40701540[Inherited retinal disorders: Current therapeutic options and future perspectives].Klinische Monatsblatter fur Augenheilkunde2025name in abstract: Luxturna
PMID 40725503Advances in Precision Therapeutics and Gene Therapy Applications for Retinal Diseases: Impact and Future Directions.Genes2025name in abstract: voretigene neparvovec
PMID 40731809Retinitis Pigmentosa: From Genetic Insights to Innovative Therapeutic Approaches-A Literature Review.Medicina (Kaunas, Lithuania)2025name in abstract: voretigene neparvovec
PMID 40736857A Practical Approach to Retinal Dystrophies.Advances in experimental medicine and biology2025name in abstract: voretigene neparvovec
PMID 40736861"Seeing Stars": The Gene Therapy Revolution.Advances in experimental medicine and biology2025name in abstract: voretigene neparvovec
PMID 40805927Pharmacoeconomic Profiles of Advanced Therapy Medicinal Products in Rare Diseases: A Systematic Review.Healthcare (Basel, Switzerland)2025name in abstract: voretigene neparvovec
PMID 40840866Retinal Viral Gene Therapy: Impact of Route of Administration on Serious Adverse Events-A Systematic Review.Clinical & experimental ophthalmology2025name in abstract: Luxturna
PMID 40864185[Gene therapy methods for rare ophthalmological diseases in the light of distributional justice-An overview].Die Ophthalmologie2025name in abstract: Luxturna
PMID 40869487Genetic Therapies for Retinitis Pigmentosa: Current Breakthroughs and Future Directions.Journal of clinical medicine2025name in abstract: voretigene neparvovec
PMID 40910102Efficacy and Safety of Voretigene Neparvovec in RPE65-Retinopathy: Results of a Phase III Trial in Japan.Ophthalmology science2025name in title: voretigene neparvovec
PMID 40911667Retinal gene therapy using epiretinal AAV-containing fibrin hydrogel implants.Science advances2025name in abstract: voretigene neparvovec
PMID 41001995SNAC: A Single-Nuclei Atlas of Capsid Distribution in Nonhuman Primate Eye.Human gene therapy2025name in abstract: voretigene neparvovec
PMID 41054259One down but many more to go: the state of gene therapy for inherited retinal disease.Regenerative medicine2025name in abstract: voretigene neparvovec
PMID 41138048Can Gene Therapy Transform the Treatment Landscape of Posterior Segment Eye Diseases? A Comprehensive Review of Recent Advancements.Drugs2025name in abstract: voretigene neparvovec
PMID 41140124Clinical and pharmacovigilance safety evaluation of LUXTURNA® (voretigene neparvovec-rzyl).Cutaneous and ocular toxicology2025name in title: voretigene neparvovec
PMID 41235102Gene Therapy in Rare Genetic Disorders: Current Progress and Future Perspectives.Current genomics2025name in abstract: Luxturna
PMID 41362291Nonclinical toxicity study duration in AAV gene therapy development: Evidence from industry survey supports adequacy of short-term assessments.Molecular therapy. Methods & clinical development2025name in abstract: Luxturna
PMID 41440982Gene Therapy for Inherited Retinal Disease: Current Strategies, Personalized Medicine, and Future Implications-A Comprehensive Review.Journal of personalized medicine2025name in abstract: voretigene neparvovec
PMID 41463332Mechanisms and Functions of Chromophore Regeneration in the Classical Visual Cycle: Implications for Retinal Disease Pathogenesis and Therapy.Biomolecules2025name in abstract: voretigene neparvovec
PMID 37704110Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation-Associated Inherited Retinal Degeneration in a Clinical Setting.Ophthalmology2024name in title: voretigene neparvovec
PMID 37715554A morphometric analysis of the retinal arterioles with adaptive optics imaging in RPE65-associated retinal dystrophy after treatment with voretigene neparvovec.Acta ophthalmologica2024name in title: voretigene neparvovec
PMID 37768368Multi-luminance mobility testing after gene therapy in the context of retinal functional diagnostics.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2024name in abstract: voretigene neparvovec
PMID 38044158Toward low-cost gene therapy: mRNA-based therapeutics for treatment of inherited retinal diseases.Trends in molecular medicine2024name in abstract: voretigene neparvovec
PMID 38218527Investing in vision: Innovation in retinal therapeutics and the influence on venture capital investment.Progress in retinal and eye research2024name in abstract: Luxturna
PMID 38279252The Clinical Findings, Pathogenic Variants, and Gene Therapy Qualifications Found in a Leber Congenital Amaurosis Phenotypic Spectrum Patient Cohort.International journal of molecular sciences2024name in abstract: Luxturna
PMID 38295874Objective Outcomes to Evaluate Voretigene Neparvovec Treatment Effects in Clinical Practice.Ophthalmology. Retina2024name in title: voretigene neparvovec
PMID 38376864Chorioretinal Atrophy Growth After Voretigene Neparvovec Retinotopically Is Connected to Retinal Functional Rescue.Translational vision science & technology2024name in title: voretigene neparvovec
PMID 38384245Recent developments in gene therapy research in India.Journal of biosciences2024name in abstract: Luxturna
PMID 38450707Clinical Pharmacology Perspective on Development of Adeno-Associated Virus Vector-Based Retina Gene Therapy.Clinical pharmacology and therapeutics2024name in abstract: voretigene neparvovec
PMID 38508214RPE65-Associated Retinal Dystrophies: Phenotypes and Treatment Effects with Voretigene Neparvovec.Klinische Monatsblatter fur Augenheilkunde2024name in title: voretigene neparvovec
PMID 38612516Retention Rates of Genetic Therapies Based on AAV Serotypes 2 and 8 Using Different Drug-Delivery Materials.International journal of molecular sciences2024name in abstract: voretigene neparvovec
PMID 38627549Voretigene neparvovec for inherited retinal dystrophy due to RPE65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice.Eye (London, England)2024name in title: voretigene neparvovec
PMID 39078952Gene therapy for retinal diseases: From genetics to treatment.Indian journal of ophthalmology2024name in abstract: Luxturna
PMID 39141279Partial rescue of the full-field electroretinogram in patients with RPE65-related retinal dystrophy following gene augmentation therapy with voretigene neparvovec-rzyl.Documenta ophthalmologica. Advances in ophthalmology2024name in title: voretigene neparvovec
PMID 39322487Adeno-associated virus therapies: Pioneering solutions for human genetic diseases.Cytokine & growth factor reviews2024name in abstract: Luxturna
PMID 39353611Erratum: RPE65-associated retinal dystrophies: phenotypes and treatment effects with voretigene neparvovec.Klinische Monatsblatter fur Augenheilkunde2024name in title: voretigene neparvovec
PMID 39439625Advances and Challenges in Gene Therapy for Inherited Retinal Dystrophies: A Comprehensive Review.Cureus2024name in abstract: Luxturna
PMID 39489915Recombinant adeno-associated virus as a delivery platform for ocular gene therapy: A comprehensive review.Molecular therapy : the journal of the American Society of Gene Therapy2024name in abstract: voretigene neparvovec
PMID 39598155Infantile Nystagmus Syndrome-Associated Inherited Retinal Diseases: Perspectives from Gene Therapy Clinical Trials.Life (Basel, Switzerland)2024name in abstract: voretigene neparvovec
PMID 39685816Novel Therapies for Inherited Retinal Dystrophies.Journal of clinical medicine2024name in abstract: voretigene neparvovec
PMID 39703610Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions.The Yale journal of biology and medicine2024name in abstract: voretigene neparvovec
PMID 39870365Correction: RPE65-associated retinal dystrophies: phenotypes and treatment effects with voretigene neparvovec.Klinische Monatsblatter fur Augenheilkunde2024name in title: voretigene neparvovec
PMID 33394965Surgical Observations From the First 120 Cases of Subretinal Gene Therapy for Inherited Retinal Diseases.Retina (Philadelphia, Pa.)2023name in abstract: voretigene neparvovec
PMID 35342187Response to "Comment on the Article: Subretinal Bleb of Voretigene Neparvovec".Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)2023name in title: voretigene neparvovec
PMID 35342188Comment on the Article: Subretinal Bleb of Voretigene Neparvovec.Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)2023name in title: voretigene neparvovec
PMID 35609955Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec.The British journal of ophthalmology2023name in title: voretigene neparvovec
PMID 35835501Subretinal deposits in young patients treated with voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy.The British journal of ophthalmology2023name in title: voretigene neparvovec
PMID 35840489RNA-targeting strategies as a platform for ocular gene therapy.Progress in retinal and eye research2023name in abstract: Luxturna
PMID 36096933Therapy with voretigene neparvovec. How to measure success?Progress in retinal and eye research2023name in title: voretigene neparvovec
PMID 36103843Gene Therapy for Inherited Retinal Disease: Long-Term Durability of Effect.Ophthalmic research2023name in abstract: voretigene neparvovec
PMID 36163489Retinal gene therapy in RPE-65 gene mediated inherited retinal dystrophy.Eye (London, England)2023name in abstract: voretigene neparvovec
PMID 36167727Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl.Cold Spring Harbor perspectives in medicine2023name in title: voretigene neparvovec
PMID 36376080Overview of Retinal Gene Therapy: Current Status and Future Challenges.Cold Spring Harbor perspectives in medicine2023name in abstract: Luxturna
PMID 36529826The Value of New: Consideration of Product Novelty in Health Technology Assessments of Pharmaceuticals.Applied health economics and health policy2023name in abstract: voretigene neparvovec

NIH grants

ProjectTitleOrganisationPIYearsLinked by
K08EY036957Insulin-accelerated surgical approach to pre-retinal gene therapyOHIO STATE UNIVERSITYMENDEL, THOMAS ALLAN2025–2026name in abstract: voretigene neparvovec
R01EB034573Engineering the biology of AAV secretion and productionDUKE UNIVERSITYASOKAN, ARAVIND2023–2026name in abstract: Luxturna
R01EY028601Retinal structure, function and response to gene therapyUNIVERSITY OF PENNSYLVANIAMORGAN, JESSICA I.W.2024–2026name in abstract: Luxturna
R01EY030227Imaging Photoreceptor FunctionUNIVERSITY OF PENNSYLVANIAMORGAN, JESSICA I.W.2026–2026name in abstract: Luxturna
R01GM149949Multimodal Label-Free Nanosensor for Single Virus Characterization and Content AnalysisSOUTHERN METHODIST UNIVERSITYKIM, MINJUN2023–2026name in abstract: Luxturna
F31EY035867Elucidating Host Responses to AAV Ocular Gene Therapy VectorsHARVARD MEDICAL SCHOOLGARDNER, APOLONIA2024–2025name in abstract: Luxturna
R01EY033049Retinal-adhesive thermoresponsive gel for AAV-mediated gene delivery to the outer retinaUNIVERSITY OF PITTSBURGH AT PITTSBURGHSAHEL, JOSE-ALAIN2022–2025name in abstract: Luxturna
R21AI180416Studies of the KIAA0319L-mediated productive transduction pathways of rAAV vectorsUNIVERSITY OF KANSAS MEDICAL CENTERQIU, JIANMING2024–2025name in abstract: Luxturna
R21EY035465Novel strategies for developing AAV tools targeting specific cell types in mammalian retinaSTANFORD UNIVERSITYWANG, SUI2024–2025name in abstract: Luxturna
R01GM082946AAV capsids and their cellular interactionsUNIVERSITY OF FLORIDAMCKENNA, ROBERT2020–2023name in abstract: Luxturna
R21AI171265Mechanism of the Membrane-Associated Accessory Protein (MAAP) in rAAV ProductionUNIVERSITY OF KANSAS MEDICAL CENTERQIU, JIANMING2022–2023name in abstract: Luxturna
R41TR004338Development of an Effective Strategy to Block Nab Activity for AAV Brain TransductionNABGEN, INC.ASKEW, CHARLES H2023–2023name in abstract: Luxturna
R01FD007226Flexible Platform for End-to-end Manufacturing of Gene Therapies to Advance Development of Treatments for Ultra-rare DiseasesMASSACHUSETTS INSTITUTE OF TECHNOLOGYHAN, JONGYOON2020–2022name in abstract: Luxturna
R21AI166293Identification of the AAVR-independent AAV entry pathwayUNIVERSITY OF KANSAS MEDICAL CENTERQIU, JIANMING2021–2022name in abstract: Luxturna
R41DK133021Rational design of AAV vectors with human hepatocyte tropism and neutralizing antibody evasionBEDROCK THERAPEUTICS, INC.LI, CHENGWEN2022–2022name in abstract: Luxturna
R41AI155038Novel strategy to block AAV neutralizing anitbody activityNABGEN, INC.LI, CHENGWEN2020–2020name in abstract: Luxturna
R41HL152923Develop humanized AAV vectors for liver targeting and neutralizing antibody evasionBEDROCK THERAPEUTICS, INC.LI, CHENGWEN2020–2020name in abstract: Luxturna

Notes

Subretinal AAV2 gene therapy for biallelic RPE65 mutation-associated retinal dystrophy; the first in vivo gene therapy licensed in the US. The FDA page lists approval letters dated 2017-12-19 and 2022-06-08 without saying which is the original, so the earliest is taken as the approval.

How to cite

voretigene neparvovec (AXP000249.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000249.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.